ArticleOncotarget2018
Systematic review and meta-analysis of selected toxicities of approved
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Pooled it
- Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis.Investigational new drugs · 2022Pooled it
- Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer.The Cochrane database of systematic reviews · 2022Pooled it
- ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.PloS one · 2020Pooled it
- Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors forJTO clinical and research reports · 2026Article
- Pralsetinib-Induced Lymphocytic Colitis.ACG case reports journal · 2026Article
- Case Report: Severe brigatinib-induced pneumonitis in a patient with EML4-ALK+ metastatic non-small cell lung adenocarcinoma.Frontiers in oncology · 2025Article
- Neurocognitive Adverse Events Related to Lorlatinib in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.Cancers · 2024Article
- Cardiovascular Toxicities Associated with Anaplastic Lymphoma Kinase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBase).Drug safety · 2023Article
- Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up.JACC. CardioOncology · 2023Article
- Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States.The oncologist · 2022Article
- Anaplastic lymphoma kinase inhibitors and their effect on the kidney.Clinical kidney journal · 2022Review
- Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.Clinical lung cancer · 2022Article
- Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study.Frontiers in pharmacology · 2022Article
- Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or MetastaticJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Article
- The DNA walk and its demonstration of deterministic chaos-relevance to genomic alterations in lung cancer.Bioinformatics (Oxford, England) · 2019Article
- The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis.Cancer management and research · 2019Article
- Linking tyrosine kinase inhibitor-mediated inflammation with normal epithelial cell homeostasis and tumor therapeutic responses.Cancer drug resistance (Alhambra, Calif.) · 2018Article
- First-line alectinib for ALK-positive lung cancer: is there room for further improvement?Drugs in context · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAnaplastic lymphoma kinase ( MATERIALS AND
methodsA systematic literature search was performed in July 2017. Studies evaluating US FDA approved doses of one of the following
resultsFifteen trials with a total of 2,005 patients with evaluable toxicity data were included in this report. There was significant heterogeneity amongst different studies. The pooled AR of death and severe adverse events were 0.5% and 34.5%, respectively. Grade 3/4 nausea, vomiting, diarrhea, and constipation were uncommon: 2.6%, 2.5%, 2.7%, 1.2%, respectively.
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.